AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $3.65, $0.06 worse than the analyst estimate of $3.71. Revenue for the quarter came in at $16.99 billion versus the consensus estimate of $16.77 billion.

GUIDANCE:

AbbVie sees FY2026 EPS of $13.87-$14.07, versus the consensus of $14.12.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Regency Centers (REG) Tops Q2 EPS by 2c
• Contineum Therapeutics, Inc. (CTNM) Tops Q2 EPS by 4c
• TFS Financial (TFSL) Tops Q3 EPS by 3c